Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700947 | 0.90 | EZH2 (0.47) | EZH2PRKCQVCP | |
| SCHEMBL24701096 | 0.87 | EZH2 (0.49) | EZH2PRKCQVCP | |
| SCHEMBL24701362 | 0.87 | EZH2 (0.50) | EZH2 | |
| SCHEMBL23169671 | 0.87 | EZH2 (0.50) | EZH2 | |
| SCHEMBL24701368 | 0.86 | EZH2 (0.60) | EZH2PRKCQVCP | |
| SCHEMBL23169326 | 0.86 | EZH2 (0.49) | EZH2 | |
| SCHEMBL23169498 | 0.86 | EZH2 (0.49) | EZH2 | |
| SCHEMBL23169380 | 0.85 | EZH2 (0.49) | EZH2 | |
| SCHEMBL23169336 | 0.85 | EZH2 (0.55) | EZH2VCP | |
| SCHEMBL23169566 | 0.84 | EZH2 (0.47) | EZH2PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | EZH2 1/4885PRKCQ 488/4885KMT2A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.